The multi-kinase oral FLT3 TKIs, sorafenib, and midostaurin, are both efficacious in the frontline setting when used in combination with chemotherapy [16, 17, 31] and sorafenib is also beneficial in the post-transplant setting [19, 20] in patients with newly diagnosed FLT3-mutated AML. Here, FLT3 is linked to acute myeloid leukemia.